Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
|Title:||An overview of plasma concentrations of asymmetric dimethylarginine (ADMA) in health and disease and in clinical studies: Methodological considerations|
|Citation:||Journal of Chromatography. B, Analytical Techniques in the Biomedical and Life Sciences, 2007; 851(1-2):42-50|
|Publisher:||Elsevier Science BV|
|John D. Horowitz and Tamila Heresztyn|
|Abstract:||Recent studies among patients including those with known coronary disease demonstrate that small elevations in asymmetric dimethylarginine (ADMA) concentrations in plasma are predictive of adverse outcomes. The precision of current methodologies for quantitation of ADMA such as HPLC, MS and ELISA is discussed with respect to many reports which appear to over-estimate ADMA levels and quote broad concentration ranges. While plasma ADMA concentrations tend to increase with age, the mean for a healthy population is between 0.4 and 0.6 microM. ADMA levels may fluctuate in normal subjects, and this needs to be considered in light of the relatively small differences in ADMA concentration between healthy normal subjects and patients.|
|Keywords:||Animals; Humans; Disease; Arginine; Chromatography, High Pressure Liquid; Clinical Laboratory Techniques; Health; Mass Spectrometry|
|Description:||Copyright © 2006 Elsevier B.V. All rights reserved.|
|Provenance:||Formerly known as Journal of Chromatography B: Biomedical Sciences and Applications|
|Appears in Collections:||Medicine publications|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.